This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.
Elegibilidad
Edad mínima: 18 YearsSexo: ALL
Criterios de inclusión
Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists
Criterios de exclusión
Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study.
Any patients judged by their physicians to be at serious suicidal risk.
Have uncontrolled narrow-angle glaucoma
Intervenciones
drug
duloxetine
Ubicaciones
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Buenos Aires, Argentina
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Capital Federal, Argentina
Patrocinadores
PrincipalEli Lilly and Company
ColaboradorBoehringer Ingelheim
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A 1-Year Safety Study of Duloxetine in Patients With Fibr... | EligiMed